Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

BPTH $1.30 0.1399 +12.06%
RNN $0.51 0.0176 +3.56%
DYAX $23.07 0.7100 +3.18%
CLVS $92.72 2.7400 +3.05%
ALPMY $13.11 0.3650 +2.86%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

GTXI $0.90 -0.0600 -6.25%
BCRX $9.25 -0.5000 -5.13%
ARGS $5.70 -0.2760 -4.62%
VSTM $1.92 -0.0650 -3.28%
CVM $0.72 -0.0240 -3.24%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | Next > | Last >>

Congressional Briefing on Oral Parity – September 30

(ASCO in Action) Sept 29, 2015 - Representatives Brian Higgins [D-NY] and Leonard Lance [R-NJ] will host a briefing on the Cancer Drug Coverage Parity Act on Wednesday, September 30, 2015. ASCO strongly supports the legislation and will attend the briefing.
read article 

Rosetta Genomics to Partner with FNApath to Provide Centralized Laboratory Testing Services for Thyroid Cancer

(CNN Money) Sept 30, 2015 - Centralized laboratory with expertise in thyroid cancer cytopathology to enhance Rosetta's new assay offering for indeterminate thyroid cancer cases; Rosetta expects to release performance data on its new assay at the upcoming 15th International Thyroid Congress.
read article 

PCCI and The US Oncology Network Collaborate to Build Patient-Centered Predictive Analytics Program

(The US Oncology Network) Sept 30, 2015 – PCCI and The US Oncology Network have entered into an agreement to develop two oncology solutions that will run on PCCI’s Pieces™ software platform.
read corporate press release 

Symbiodx and Cure Forward Partner to Advance Precision Medicine

(Yahoo! Finance) Sept 29, 2015 - Symbiodx, a leading molecular reference laboratory in the Pacific Northwest, and Cure Forward, a multisided technology platform to support patient engagement, today announced a new collaboration to advance precision medicine.
read article 

Real Precision Medicine Requires Real Access To Patient Data

(Forbes) Sept 29, 2015 - This guest post was written by Kathy Giusti, the founder and executive chairman of the Multiple Myeloma Research Foundation (MMRF) and member of President Obama’s Precision Medicine Initiative Working Group.
read article 

Blueprint Medicines Receives FDA Orphan Drug Designation for Novel Drug Candidate for Treatment of Hepatocellular Carcinoma

(StreetInsider) Sept. 30, 2015 - Blueprint Medicines today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its novel drug candidate BLU-554 for the treatment of hepatocellular carcinoma (HCC).
read article 

Jazz Pharmaceuticals Announces U.S. FDA Acceptance for Filing with Priority Review of NDA for Defibrotide for Hepatic Veno-Occlusive Disease

(Morningstar) Sept 30, 2015 - Jazz Pharmaceuticals plc today announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted for filing with Priority Review its recently submitted New Drug Application (NDA) for defibrotide.
read article 

UK Launch for Roche's Perjeta in Early Breast Cancer

(PharmaTimes [UK]) Sept 30, 2015 - Around 2,000 women in the UK with an aggressive form of breast cancer could now benefit from Roche’s Perjeta earlier in the treatment pathway after regulators expanded the drug’s license.
read article 

Kura Oncology Initiates Phase 2 Study of Tipifarnib in Peripheral T-cell Lymphoma

(Morningstar) Sept 30, 2015 - Kura Oncology, Inc. today announced it has initiated a Phase 2 clinical trial of tipifarnib in patients with peripheral T-cell lymphoma (PTCL).
read article 

Infinity Announces Enrollment Of 120th Patient In Phase 2 DYNAMO™ Study Evaluating Duvelisib In Indolent Non-Hodgkin Lymphoma

(Infinity) Sept 30, 2015 - Infinity Pharmaceuticals, Inc. today announced that the 120th patient has been enrolled in DYNAMO™, a Phase 2 study in patients with refractory indolent non-Hodgkin lymphoma (iNHL) evaluating the safety and efficacy of duvelisib, an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma.
read corporate press release 

Ignyta Announces Initiation of STARTRK-2 Phase 2 Clinical Trial of Entrectinib

(Yahoo! Finance) Sept 30, 2015 - Ignyta, Inc., a precision oncology biotechnology company, today announced the initiation of its Phase 2 clinical trial of entrectinib, the company’s proprietary oral tyrosine kinase inhibitor targeting solid tumors that harbor activating alterations to NTRK1, NTRK2, NTRK3, ROS1 or ALK.
read article 

Celsion Corporation Enrolls First Patient in the OVATION Study

(CNN Money) Sept 30, 2015 - First line, phase 1b trial to assess immunotherapy combining GEN-1 with neo-adjuvant therapies in newly diagnosed ovarian cancer patients.
read article 

Cerulean Announces CRLX101 Advances to Second Stage of Phase 2 Clinical Trial of CRLX101 in Combination with Avastin® in Relapsed Ovarian Cancer

(MarketWatch) Sept 30, 2015 - Cerulean Pharma Inc. today announced that CRLX101 has achieved the pre-defined, gating criterion for advancement into stage two of an open label, single-arm Phase 2 investigator-sponsored trial (IST) of CRLX101 in combination with Avastin® in patients with recurrent cisplatin-resistant ovarian, tubal and peritoneal cancer.
read article 

OncoGenex Announces Completion of Patient Enrollment in Borealis-2™ Clinical Trial Evaluating Apatorsen in Relapsed or Refractory Metastatic Bladder Cancer

(Morningstar) Sept 30, 2015 - OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2™, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients.
read article 

Galena Biopharma Collaborates With the National Cancer Institute on a Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Ductal Carcinoma in Situ Patients

(NASDAQ) Sept 30, 2015 - Galena Biopharma, Inc. today announced a collaboration with the National Cancer Institute (NCI) to initiate a new, Phase 2 clinical trial with NeuVax™ (nelipepimut-S) in patients diagnosed with Ductal Carcinoma in Situ (DCIS).
read article 

Cancer Drugs Disguised As Platelets May Be More Effective

( Sept 29, 2015 - Researchers have developed a method to coat cancer drugs with membranes from a patient's own platelets, which helped the drugs stay in the body longer to attack primary tumors and circulating tumor cells that can cause cancer to spread.
read article 

Inroads Against Leukemia

(Harvard Gazette) Sept 29, 2015 - Potential for halting disease in molecule isolated from sea sponges.
read article 

Consider Frailty, Not Only Age, When Choosing Myeloma Drugs

(Medscape Medical News) Sept 27, 2015 - Functional status, as well as chronologic age, is significantly associated with survival in multiple myeloma, according to "real-life" registry data from the Netherlands.
read article (free registration required) 

Carfilzomib Quadruplet for Myeloma Induction Looks Tolerable

(Medscape Medical News) Sept 28, 2015 - Quadruplet therapy that consists of the newer-generation proteasome inhibitor carfilzomib (Kyprolis, Onyx Pharmaceuticals), cyclophosphamide, lenalidomide (Revlimid, Celgene), and dexamethasone, is safe and well tolerated, according to results from the first large trial to assess its use in newly diagnosed myeloma patients who are eligible for transplantation.
read article (free registration required) 

New Prostate Cancer Treatments Could Target Metabolism

(University of Houston) Sept 29, 2015 - A UH researcher and his team were awarded nearly $2.3 million in funding from the NIH’s National Cancer Institute to find a more effective treatment for prostate cancer. The standard treatment methods in the advanced stage of the disease lose effectiveness after about one to two years.
read article 

MRI Technique Could Reduce Need for Breast Biopsies

(RSNA) Sept 29, 2015 - A magnetic resonance (MR) breast imaging technique that uses no ionizing radiation or contrast agent could reduce unnecessary biopsies by providing additional information about suspicious findings on X-ray screening mammography, according to a new study published online in the journal Radiology.
read press release 

"Fine Tuning" Engineered T Cells May Extend Immunotherapy Approach to More Cancer Types

(NCI/Cancer Currents Blog) Sept 28, 2015 - Engineering immune cells to have a decreased ability to bind to their targets on cancer cells doesn’t appear to impair their ability to kill cancer cells, but it may cause them to spare healthy cells that have low levels of the same molecular target.
read article 

Clovis Oncology Announces U.S. and E.U. Regulatory Milestones for Rociletinib in the Treatment of Advanced EGFR-Mutant T790M+ Non-Small Cell Lung Cancer

(Investor’s Business Daily) Sept 29, 2015 - FDA grants priority review status to rociletinib New Drug Application; assigns action date of March 30, 2016; EMA accepts Marketing Authorization Application for rociletinib; awards accelerated assessment.
read article 

Cancer Drugs Aren't As Cost-Effective As They Used To Be

(Forbes) Sept 30, 2015 - Cancer drugs have become increasingly expensive in recent years. No one blinks anymore when a new lung cancer or colon cancer treatment comes to market priced at more than $100,000 per patient.
read article 

The Drug Price Conundrum: A Q&A with Memorial Sloan Kettering's Dr. Peter B. Bach

(Fortune) Sept 29, 2015 - Drug prices: where the free market and public interest collide.
read article